Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals highlighted 12 abstracts featuring their FDA-approved menin inhibitor Revuforj (revumenib) accepted for presentation at the European Hematology Association (EHA) 2026 Congress. The data demonstrate strong activity across various subtypes of acute leukemia, favorable tolerability, promising post-transplant maintenance outcomes…